r Offspring of overweight and obese women are at greater risk for respiratory complications at birth.
Introduction
Babies born to overweight or obese women are at greater risk of respiratory distress syndrome (RDS) (Mazumder et al. 2011; McIntyre et al. 2012; Lock et al. 2013; McGillick et al. 2017) . Coinciding with the worldwide obesity epidemic, the proportion of women entering pregnancy overweight or obese has increased significantly in recent years (LaCoursiere et al. 2005; Chu et al. 2009; Woolcott et al. 2016) . In late gestation, pregnant women normally become insulin resistant. This is essential to drive the transfer of substrates, particularly glucose across the placenta to the developing fetus, to ensure that the demands of normal growth are met (King, 2006) . Obese women are significantly more insulin resistant before pregnancy and remain this way throughout gestation, leading to a higher risk of developing gestational diabetes (Butte, 2000; Catalano & Ehrenberg, 2006) . Historically, clinical studies have reported that uncontrolled diabetic mothers have a 6-fold increased risk of delivering neonates with RDS when compared to non-diabetic mothers (Robert et al. 1976) . Furthermore, 34% of the infants of diabetic mothers admitted to neonatal intensive care units present with RDS of varying severity resulting in substantial morbidity and economic burden (Cordero et al. 1998) . It has been demonstrated that exposure of the fetus in animal or human studies to changes in maternal nutrition results in altered gene expression that may be programmed within tissues in early life and result in the emergence of a specific phenotype in postnatal life (Muhlhausler et al. 2006; McMillen et al. 2009; Zhang et al. 2010) . As a result of these changes, individuals exposed to maternal undernutrition or overnutrition when in utero are at risk of the emergence of insulin resistance in tissues of metabolic importance as they age. In addition, maladaptation of the pulmonary circulation impedes the cardiorespiratory transition at birth, which can predispose to pulmonary hypertension of the newborn leading to reduced oxygenation and requirement for ventilatory support (Storme et al. 2013) .
Pulmonary surfactant is a complex mixture of lipids and proteins that functions to reduce surface tension at the air-liquid interface, prevent alveolar collapse and promote pulmonary immunity (Goerke & Clements, 1985; Pérez-Gil & Weaver, 2010; Orgeig et al. 2015b) . A reduction in surfactant production is associated with the pathogenesis of RDS in newborns (Avery & Mead, 1959) . Type II alveolar epithelial cells are responsible for the synthesis of both the lipid and protein components of pulmonary surfactant. This complex is stored in cytoplasmic inclusion bodies known as lamellar bodies until they are secreted into the alveolar fluid lining in response to a range of stimulatory factors (Rooney, 2001 ) to form a surface active film at the air-liquid interface (Goerke, 1998; Veldhuizen et al. 1998) . Surfactant phospholipid synthesis occurs through multiple biochemical pathways, some of which rely on key rate limiting enzymes such as phosphate cytidylyltransferase 1, choline, alpha (PCYT1A or CCTα in humans). Changes to the intrauterine environment seen in overweight or obese pregnancies, such as increased plasma glucose and insulin concentrations, may antagonise surfactant protein and phospholipid synthesis as previously discussed (Lock et al. 2013; McGillick et al. 2017) .
While the molecular mechanisms that underlie the adverse effects of increased glucose and/or insulin exposure on lung development are not fully understood, there is emerging evidence that this may relate to inhibition of critical processes in lung development. Increased plasma glucose and/or insulin concentrations are associated with decreases in the number of type II alveolar epithelial cells and lamellar bodies per alveolar cell (Gewolb, 1996) , abnormalities in lipid metabolism, decreased surfactant protein (SFTP) mRNA expression (Rayani et al. 1999) and a reduction in SFTP-A in amniotic fluid (Snyder et al. 1988) . Furthermore, maternal obesity may also be linked to persistent pulmonary hypertension in newborns, which has been associated with RDS (Storme et al. 2013) . Previous studies by us (Orgeig et al. 2010; McGillick et al. 2014 McGillick et al. , 2016b and others (Gagnon et al. 1999; Cock et al. 2001; Sozo et al. 2009 ) have shown that surfactant maturation during late gestation is modulated by changes in the intrauterine environment, including oxygen and nutrient availability. This supports the suggestion that changes in fatty acid and glucose metabolism in the lung in the obesogenic environment during pregnancy will significantly disrupt fetal lung maturation. In this study, we therefore aimed to test the hypothesis that maternal late gestation overnutrition (LGON) will decrease surfactant expression in fetal and lamb lungs via altered regulatory pathways of surfactant metabolism in utero.
Methods

Ethical approval
Experimental protocols for animal work were approved for these projects by the University of Adelaide Animal Ethics Committee and performed according to the guidelines of the Australian code of practice for the care and use of animals for scientific purposes. Experiments were designed and reported with reference to the ARRIVE guidelines (Kilkenny et al. 2010) . The authors have read, and the experiments comply with, the policies and regulations of The Journal of Physiology (Grundy, 2015) .
Animals
In total, 35 pregnant Merino ewes and their fetuses or lambs were used in these studies. Each ewe was housed in an individual pen in an indoor housing facility that was maintained at a constant ambient temperature of of 20-22°C and a 12 h light-dark cycle. Detailed information on housing, maternal nutrient intake and plasma glucose, leptin and insulin concentrations has been previously published for these animals (Muhlhausler et al. 2002 (Muhlhausler et al. , 2006 Rattanatray et al. 2014) .
Pregnant ewes were fed a standard maintenance diet as previously described (Muhlhausler et al. 2002) . At 115 days' gestation (equivalent to ß25 weeks' gestation in humans), which is representative of the late canalicular/early saccular stage of lung development (Harding & Bocking, 2001) , ewes were randomly assigned to either a Control or LGON group. The total metabolisable energy intake for the Control group (0.17 ± 0.01 MJ kg −1 day −1 ) was defined as 100%, whereas that for the LGON group (0.26 ± 0.02 MJ kg −1 day −1 ) was ß55% greater. The feed allowance of all ewes was proportionately increased by 15% every 10 days in order to meet the increasing substrate demands of the growing fetus. Data on feeding, appetite regulation and fat development have previously been published for these animals (Muhlhausler et al. 2002 (Muhlhausler et al. , 2006 (Muhlhausler et al. , 2007b . Ewes were then further allocated to either the Fetal or Lamb cohort resulting in four groups (Fetal cohort: Control n = 6, LGON n = 8; Lamb cohort: Control n = 12, LGON n = 9).
Fetal cohort
Surgery was performed between 103 and 113 days' gestation on pregnant ewes as previously described to implant fetal vascular catheters into the carotid artery, jugular vein and amniotic cavity (Muhlhausler et al. 2002) under appropriate anaesthesia (induced by I.V. injection of sodium thiopentone (1.25 g I.V.; Pentothal, Rhone Merieux, Australia) and maintained with 2.5-4% halothane (Fluothane; ICI, Australia) in oxygen). During surgery, intramuscular injections of antibiotics (2 ml procaine penicillin 250 mg ml −1 , dihydrostreptomycin 250 mg ml −1 , procaine hydrochloride 20 mg ml −1 ; Lyppards, Australia; or 100 mg ml −1 oxytetracycline hydrochloride; Pfizer, Australia) were administered to each ewe and fetus, respectively. Ewes were allowed at least 3 days to recover from surgery to ensure that any residual effects from anaesthesia or anibiotics would not interfere with the overnutrition experimental protocol. Blood samples were collected three times per week for blood gas measurements to monitor fetal wellbeing using an ABL 520 analyser (Radiometer, Copenhagen, Denmark) temperature corrected to 39°C and plasma samples were stored at −20°C for subsequent analysis.
Lamb cohort
Ewes were allowed to deliver spontaneously at term (Control: 150.2 ± 0.8 days, LGON: 149.6 ± 0.6 days) and were provided with the same feed allocation that was calculated to meet the metabolisable energy requirements of lactation (Muhlhausler et al. 2006 (Muhlhausler et al. , 2007a . The day of birth was designated as day 1. Birth weight, crown-rump length, abdominal circumference and shoulder height were recorded within 6 h of birth. These measures were also recorded each day for the first 5 days of life and at least once every 2 days afterwards until postnatal day 30. Venous blood samples were collected within 24 h of birth after a 2 h fast on days 1-5 and every 3 days afterwards until postnatal day 30. All blood samples were centrifuged and plasma stored at −20°C for later analyses.
Post-mortem tissue collection
At 139-141 days' gestation pregnant ewes and their fetuses were killed with an overdose of sodium pentobarbitone (Virbac, Australia) and fetuses were delivered by hystereotomy. Lambs 30 days after birth were killed with intravenous overdose of sodium pentobarbitone. Body weight was determined and samples from major organs, including the lungs, were dissected and weighed, and samples were snap frozen in liquid nitrogen and stored at −80°C for subsequent determination of gene expression or immersion fixed in 4% paraformaldehyde in 0.2 M phosphate buffer for subsequent processing and J Physiol 595.21 histological analyses. Fixed lung tissue was embedded in paraffin in a single random orientation and sectioned by a trained individual who was blinded to the treatment groups. This cohort was not specifically run with lung analysis as a primary outcome; hence other samples and analyses such as bronchoalveolar lavage and functional measures were not available/possible.
Quantification of mRNA within the lung
Total RNA was extracted from frozen lung tissue of each fetus and lamb (Fetal cohort: Control n = 6, LGON n = 8; Lamb cohort: Control n = 12, LGON n = 9; ß50 mg) using QIAzol Lysis Reagent Solution and Qiagen miRNeasy purification columns as per the manufacturer's guidelines (Qiagen, Hilden, Germany) as previously described (McGillick et al. 2014 (McGillick et al. , 2016b .
Quantitative real-time RT-PCR. The geNorm component of qbaseplus 2.0 software (Biogazelle, Gent, Belgium) was used to determine the most stable reference genes from a panel of candidate reference genes (Vandesompele et al. 2002) and the minimum number of reference genes required to calculate a stable normalisation factor as previously described (Soo et al. 2012; McGillick et al. 2013) . For qRT-PCR data output normalisation, three stable reference genes (Table 1 ; ACTB, PPIA and either PGK1 (fetuses), or YWHAZ (lambs)) were run in parallel with target genes as previously described (Soo et al. 2012; McGillick et al. 2013 McGillick et al. , 2016b .
Previously published and specifically designed primer sets (Table 1) were validated and optimised as previously described (Orgeig et al. 2010; McGillick et al. 2013) . The expression of genes involved in surfactant maturation PCYT1A) , glucose transport (SLC2A1, SLC2A4), glucocorticoid availability and activity (HSD11B-1, HSD11B-2, NR3C1), fatty acid metabolism (PPARG, PPARGC1A, FASN, FATP1, CD36, CPT1, ACACA, FABP) as well as transcription and growth factors (RXRA, IGF1, IGF1R, TGFB1, CEBP) were measured in lung tissue by qRT-PCR using Fast SYBR R Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) in a final volume of 6 μl on a ViiA7 Fast Real-time PCR system (Thermo Fisher Scientific) as previously described (Soo et al. 2012; McGillick et al. 2013) . The abundance of each transcript relative to the abundance of stable reference genes (Hellemans et al. 2007 ) was calculated using DataAssist 3.0 analysis software (Thermo Fisher Scientific) and expressed as mean normalised expression (Soo et al. 2012; McGillick et al. 2013) . Outliers were defined as values that were ±2 standard deviations from the mean for each treatment group and were removed from the analysis; n values for each treatment group are included in Tables 2-4.
Quantification of SFTP-B positive cells within the fetal and lamb lung
Immunohistochemistry was performed using a rabbit anti-human mature SFTP-B antibody (1:1000, WRAB-48604, Seven Hills Bioreagents, Cincinnati, OH, USA) as previously described (Lock et al. 2015; McGillick et al. 2016a,b) . All sections were counterstained with Mayer's haematoxylin (Sigma-Aldrich, St Louis, MO, USA). Negative Control slides (primary antibody negative control 1 and rabbit serum negative control 2; Fig. 5A and B) were incubated overnight at 4°C in parallel with test slides under the same experimental conditions as described previously (Lock et al. 2015; McGillick et al. 2016a,b) . Stained sections (Fetal cohort: Control n = 6, LGON n = 8; Lamb cohort: Control n = 12, LGON n = 9) were examined using Visiopharm new Computer Assisted Stereological Toolbox (NewCAST) software (Visiopharm, Hørsholm, Denmark) as described previously (Lock et al. 2015; McGillick et al. 2016a,b) . Sixty counting frames (×600 magnification) of the alveolar epithelium were randomly selected per tissue section. Positive staining was confirmed with the presence of cuboidal cells exhibiting cytoplasmic staining within the alveolar epithelium of lung tissue sections. Point-counting using an unbiased counting frame with an area of 20,000 μm 2 on immersion fixed tissue was used to estimate the numerical density of SFTP-B positive cells within the alveolar epithelium of fetal lung tissue sections as described previously (Lock et al. 2015; McGillick et al. 2016a,b) .
Quantification of plasma cortisol concentration
Cortisol was extracted from plasma samples using dichloromethane (Fetal cohort: Control n = 5, LGON n = 8; Lamb cohort: Control n = 12, LGON n = 9) and measured with radioimmunoassay (Perkin Elmer, Waltham, MA, USA) as previously described (Warnes et al. 2003; Orgeig et al. 2010; Poudel et al. 2015) . The sensitivity of the assay was 0.2 nM, and the intra-assay and inter-assay coefficients of variation were < 10%.
Plasma glucose and non-esterified fatty acids
Plasma glucose concentration (Fetal cohort: Control n = 5, LGON n = 6; Lamb cohort: Control n = 11, LGON n = 8) was measured by enzymatic analysis using hexokinase and glucose-6-phosphate dehydrogenase to measure the formation of NADH photometrically at 340 nm (Konelab 20XTi, Program Version 6.0 automated analysis system, Thermo Fisher Scientific). Non-esterified fatty acids (NEFAs) were quantified using a Wako NEFA kit (Wako Life Sciences, Mountain View, CA, USA) and measured photometrically at 550 nm using the Konelab 20XTi (Thermo Electron Oy, Vantaa, Finland) (Muhlhausler et al. 2009b) . 
Statistical analyses
As the stable reference genes selected for the fetuses and lambs were not the same, the data are not directly comparable and the fetal and lamb data sets were analysed separately. Our specific research question relates to differences in outcome between the Control and LGON groups in all measures and our data analysis has been carried out in consultation with a biostatistician. In the case of mRNA expression data, all genes were chosen a priori due to their known roles in normal development to prepare the lung for the successful transition to air-breathing at birth and have previously shown changes in response to altered intrauterine conditions (Walther et al. 1991; Flecknoe et al. 2003; Jesse et al. 2009; McGillick et al. 2013 McGillick et al. , 2016a . Therefore, we have chosen a statistically significant P value of ࣘ 0.05 with no correction for multiple comparisons (Rothman, 1990; Greenland et al. 2016) . All data are presented in tables as means ± SD or mean normalised expression ± SD in the J Physiol 595.21 case of gene expression data. Data were analysed using an effect size calculator (Excel) and adjusted P-value for mean difference (Student's 2-tailed t test) in addition to the effect size and 95% confidence intervals for all measures.
Results
Impact of LGON on fetal and lamb body and lung weights
There were no significant differences in body weight, crown-rump length, abdominal circumference, or lung weight between the Control and LGON groups in either fetuses or lambs ( Table 2) .
Effect of LGON on fetal and lamb plasma glucose, insulin and NEFA concentrations
Plasma glucose and insulin concentrations were significantly higher in LGON fetuses compared to Control fetuses from 115-141 days' gestation as previously reported (Muhlhausler et al. 2002 (Muhlhausler et al. , 2003 . There was, however, no significant difference in the average plasma NEFA concentrations (Muhlhausler et al. 2002 (Muhlhausler et al. , 2003 . 
Effect of LGON on surfactant protein mRNA expression
The mRNA expression of SFTP-A, SFTP-B and SFTP-C in the fetal lung was reduced in LGON compared to Control fetuses (P < 0.05, Fig. 1A-C) , but there was no significant difference in the mRNA expression of SFTP-D between Control and LGON fetuses (Fig. 1D ). There were no differences in the mRNA expression of SFTP-B, SFTP-C and SFTP-D in the lungs of LGON compared to Control lambs at 30 days after birth, while SFTP-A mRNA expression was increased in the lungs of lambs in the LGON group compared to Controls (P < 0.05, Fig. 2A-D) .
Effect of LGON on the regulation of surfactant lipid synthesis
There was a significant decrease in the mRNA expression of PCYT1A, a key rate limiting enzyme in the production of surfactant phosphatidylcholine, in LGON fetuses compared to Controls (P < 0.05, Fig. 1E ). In contrast, the mRNA expression of this same enzyme was significantly increased in the lungs of LGON compared to Control lambs (P < 0.05, Fig. 2E ). 
Effect of LGON on expression of genes regulating glucocorticoid availability and activity in the lung
LGON did not significantly alter the mRNA expression of HSD11B-1, HSD11B-2 or NR3C1 in the lungs of either fetuses or lambs (Tables 3 and 4 
Effect of LGON on the mRNA expression of glucose transporters in the lung
The mRNA expression of glucose transporters SLC2A1 and SLC2A4 in the lungs was significantly reduced in LGON fetuses compared to Controls (P < 0.05, Fig. 3 ). There was no difference, however, in the expression of these markers between LGON and Control lambs (Table 4) .
Effect of LGON on the mRNA expression of molecules involved in fatty acid metabolism
The mRNA expression of PPARG in the lungs was significantly increased in LGON compared to Control lambs (P < 0.05, Fig. 4B ), but was not different between treatment groups in fetuses.
LGON had no effect on the mRNA expression of PPARGCIA in the lung in either fetuses or lambs (Tables 3 and 4 ). There was a significant increase in the mRNA expression of FASN and FATP1 in the lungs of LGON lambs ( Fig. 4C and D) ; however, the mRNA expression of these factors was not different between Control and LGON fetuses (Table 3) . CPT1, ACACA, CD36 and FABP mRNA expression was not different between the Control and LGON groups in either fetuses or lambs (Tables 3 and 4) . 
Effect of LGON on the mRNA expression of transcription and growth factors in the lung
There was no significant difference in the mRNA expression of transcription factors or receptors SREBF-1, CEBP, RXRA, IGF1 or IGF1R in the lungs between the LGON and Control groups in either fetuses or lambs (Tables 3 and 4 ). The mRNA expression of TGFB1 in the lungs was significantly increased in LGON compared to
Control lambs (P < 0.05, Fig. 4A ), but was not different between treatment groups in fetuses.
Effect of LGON on numerical density of SFTP-B positive cells in the alveolar epithelium
There was a significant decrease in the numerical density of SFTP-B positive staining cells in the lung of LGON fetuses compared with Controls (P < 0.05; Fig. 5G ); however, there was no difference in the lambs (Fig. 5H) .
Discussion
Maternal overnutrition during late gestation is associated with significant increases in maternal glucose concentrations and in fetal glucose and insulin concentrations (Muhlhausler et al. 2002) , mimicking the changes that are also present in a mother with gestational diabetes in late pregnancy. Thus, an important feature of the study is that we were able to test the specific effects of an increase in fetal glucose and insulin concentrations on the lung without the additional complications of fetal overgrowth. We have shown previously that the changes in fetal glucose and insulin associated with maternal overnutrition in late gestation do not result in changes in fetal or lamb growth up to 30 days of age (Muhlhausler et al. 2002 (Muhlhausler et al. , 2006 . We have demonstrated, however, that maternal overnutrition does result in changes in the body composition, such that lambs of overnourished ewes have a greater relative subcutaneous fat mass compared to lambs of control ewes at 30 days of age (Muhlhausler et al. 2006) . This highlights that exposure to maternal overnutrition in utero can alter the body composition of the postnatal animal. Furthermore, maternal overnutrition in humans may occur before, during or throughout all of pregnancy and thus the effects on fetal growth may be less severe with only a late gestation protocol. Regardless, maternal obesity is associated not only with an increased risk of increased fetal growth but also an increased risk of reduced fetal growth (McGillick et al. 2017) . The outcomes of maternal overnutrition on the fetus are therefore variable depending upon the timing of exposure onset. In the fetus, LGON reduced mRNA expression of SFTP-A, -B and -C in the lungs and this effect was mirrored in our immunohistochemistry data where we found a significant decrease in the numerical density of SFTP-B positive cells in the alveolar epithelium. However, in the LGON lambs 30 days after birth, there was normalisation of SFTP mRNA expression including a significant increase in SFTP-A and no effect on the numerical density of SFTP-B cells in the alveolar epithelium. SFTP-A is critically involved in innate immunity and the pulmonary inflammatory response; however, it may also act in a negative feedback manner by inhibiting surfactant phospholipid secretion (Wright & Dobbs, 1991) . The decrease in SFTP-A mRNA expression observed in LGON fetuses may therefore be linked to the increased risk of airway disease seen in offspring of obese mothers (McGillick et al. 2017) . Conversely, the upregulation of SFTP-A mRNA observed in the 30-day-old lambs may provide some innate immune benefits. Taken together, these data suggest that fetuses exposed to LGON may exhibit reduced capacity to lower the surface tension at the alveolar air-liquid interface at birth, thereby increasing the risk of developing neonatal respiratory complications. However, there is accelerated maturation of the lung after birth, so that these deficits do not appear to persist beyond the immediate postnatal period.
Phosphate cytidylyltransferase 1, choline, alpha (PCYT1A), also known as choline-phosphate cytidylyltransferase alpha (CCTα) in humans, is a key rate limiting enzyme in the production of phosphatidylcholine and dipalmitoylphosphatidylcholine, the most abundant surfactant phospholipids necessary for reducing the surface tension of the surfactant film and preventing alveolar collapse (Rooney, 2004) . Taken together with the reduced number of surfactant producing cells in the alveolar epithelium, the decreased mRNA expression of PCYT1A in LGON fetuses indicates that these fetuses may have a reduced capacity for surfactant phospholipid production via this de novo synthetic pathway. This effect was largely reversed in the LGON lambs, where PCYT1A mRNA expression was increased compared to Controls. Further studies in lambs at additional ages, as well as measurements of surfactant phospholipids in alveolar lavage (Warburton, 1983) , would be beneficial to determine the time course of this enzyme's expression and surfactant phospholipid composition across gestation and after birth in response to LGON.
The increased expression of key genes involved in fatty acid metabolism, namely fatty acid synthase (FASN) and fatty acid transport protein (FATP1), in LGON lambs suggests a potential increase in the capacity for uptake of fatty acids via transporters and the synthesis of fatty acids within the lamb lung. Increased expression of FASN in particular may have a direct impact upon the production of surfactant phospholipids, since fatty acid synthase is a key enzyme in the production of palmitate, a major component utilised in surfactant phospholipid production (Schiller & Bensch, 1971) . Interestingly, there was also increased expression of TGFB1. This may have implications for the normal regulation of surfactant production as TGFB1 antagonises the stimulatory effects of glucocorticoids on fatty acid synthesis in fetal rodent lungs (Agassandian & Mallampalli, 2013) .
The observed increase in average plasma glucose concentration of LGON fetuses during late gestation J Physiol 595.21 (Muhlhausler et al. 2002) may contribute to the significant reduction in SFTP mRNA expression that we observed in this group. We have previously demonstrated that simulated uncontrolled maternal diabetes via direct intrafetal glucose infusion, which raised both the plasma glucose and insulin concentrations of fetuses to a much greater extent than LGON, was associated with a significant decrease in the gene expression of the SFTPs (McGillick et al. 2014) . The lack of change in plasma cortisol concentration from the day before post-mortem combined with an absence of any changes in mRNA expression data of HSD11B-1 and -2 and NR3C1 indicates that LGON had no effect on glucocorticoid availability or action in the lung of either fetuses or lambs. In the normal developing lung, cortisol plays the most crucial role in preventing RDS by increasing surfactant phospholipid production and thinning the alveolar walls. However, it has been proposed that insulin antagonises the stimulatory effects of glucocorticoids on pulmonary surfactant metabolism in a dose-dependent manner (Dekowski & Snyder, 1995) . In addition, we have previously reported decreased expression of genes regulating glucocorticoid availability (HSD11B-1 and NR3C1) in the fetal lung after a 10-day glucose infusion (McGillick et al. 2014) . Hence, it may be that if the LGON were of greater severity or duration, as seen with overweight and obese pregnancies in humans, we may expect to see larger increases in plasma glucose and insulin concentrations and consequently a decrease in cortisol availability in the lung.
The induction of SLC2A1 in the lungs is glucosemediated and is usually upregulated by decreasing plasma glucose concentrations (Simmons et al. 1993) . In contrast, SLC2A4 is mediated by changes in plasma insulin concentration and is most predominately expressed in adipose and skeletal muscle (Zorzano et al. 2005) . The decreased SLC2A1 mRNA expression in response to LGON in the lungs of the fetus could be explained by the increased plasma glucose concentration between 135 and 141 days. However, the decreased SLC2A4 mRNA expression was unexpected due to the increased insulin concentration observed between 115 and 141 days' gestation. These results, in addition to the lack of gene changes in our glucose infusion model (McGillick et al. 2014) , may suggest that the observed changes in SLC2A4 in the fetal lung following LGON may not be regulated directly by glucose and insulin availability in the blood but via a more indirect regulation at the tissue level.
PPARγ is an important factor involved in surfactant production and is required for activation of pulmonary lipofibroblasts. In particular, this factor activates the differentiation of pulmonary lipofibroblasts, in turn increasing leptin secretion and activating type II alveolar epithelial cells (Rehan & Torday, 2012) . The increased PPARG mRNA expression in the lungs of LGON lambs, but not in LGON fetuses, suggests an increase in expression of key molecules involved in leptin-activated surfactant production in postnatal life, indicating a possible increase in activation of alveolar type II cells and normalised surfactant expression shortly after birth. This speculation is consistent with the finding that the numerical density of SFTP stained cells in the alveolar epithelium was not different between Control and LGON lambs.
This study is the first to show impaired surfactant maturation in the fetal lung in response to late gestation maternal overnutrition and altered glucose transport and fatty acid metabolism in the lung after birth. These findings raise interesting questions regarding the effects of the growing obesity epidemic on fetal respiratory outcomes that has implications both at birth and in later life. The changes observed in the lungs of the fetuses included significant decreases in SFTP mRNA expression and the numerical density of surfactant positive cells in the alveolar epithelium following exposure to
LGON, which in turn may directly affect the surface tension at the air-liquid interface of the alveoli at birth, resulting in an increase in the risk of respiratory complications and RDS at birth. The observed decrease in the mRNA expression of PCYT1A, SLC2A1 and SLC2A4 may point to the mechanism for the decreased synthetic activity of surfactant phospholipids. Countering these findings, we have observed a significant increase in the mRNA expression of genes regulating surfactant maturation (SFTP-A) and fatty acid metabolism (PPARG, FASN and FATP1) in the postnatal lung following exposure to maternal LGON. These results suggest a potential upregulation of genes involved in lung maturation/function and surfactant synthesis after birth in LGON offspring, leading to the observed acceleration in surfactant maturation. Thus, how maternal overnutrition impacts on fetal and neonatal lung development is likely to be a complex issue programmed at the structural and molecular level that requires further detailed analysis to understand how these factors work synergistically or antagonistically to regulate the respiratory outcomes of these neonates at birth and in postnatal life.
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Translational perspective
Maternal overweight and obesity during pregnancy is linked with a number of respiratory complication in offspring. We evaluated the effect of late gestation maternal overnutrition on structural and molecular regulation of surfactant system development during late gestation and after birth. We have provided evidence of negative effects of maternal overnutrition on surfactant system maturation in the fetal lung with decreased mRNA expression of surfactant components and decreased numerical density of surfactant producing cells in the alveolar epithelium. Despite the negative effects of maternal overnutrition on fetal lung development, there was normalisation in surfactant protein expression in lambs 1 month after birth, indicating accelerated maturation in the lung via upregulated fatty acid metabolism. These data indicate that maternal overnutrition during late gestation can result in an increased risk of respiratory complications at birth and may be an additional risk factor for premature infants that already have a high risk of respiratory distress syndrome. After birth there is an increased maturation of the surfactant system, amongst changes in glucose transport and fatty acid metabolism; however, the mechanisms by which maternal overnutrition may affect long term lung function is unclear. Thus, maternal overnutrition is a complex issue that requires further detailed analysis to understand how these factors work synergistically or antagonistically to regulate the respiratory outcomes of these neonates at birth and in postnatal life.
